Tools
Stock profile

NEUROCRINE BIOSCIENCES INC (NBIX)

NBIX · Latest close $162.86 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$162.86
As of Nov 18, 2026
Tracked funds holding
2 of 149
2026 Q2 13F filings
Opened / added
0 / 2
vs previous quarter
Trimmed / exited
2
vs previous quarter

NEUROCRINE BIOSCIENCES INC (NBIX) is held by 2 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 2 funds adding and 2 funds trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $3.2M sold). Latest close $162.86 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 3, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-3.2M
Fundamentals
Revenue · FY2025
Red flags
none flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

RTW Investments · Dodge & Cox Funds — 2 tracked funds hold NBIX. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 15 sales ($3.2M). Insider trading

Often held alongside

AMGEN INC (AMGN) · GILEAD SCIENCES, INC. (GILD) · Taysha Gene Therapies, Inc. (TSHA) · BIOGEN INC. (BIIB) · Immunovant, Inc. (IMVT) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
RTW Investments1.82%1,267,925ADDED (+19.4%) Q3 filed Nov 16
Dodge & Cox Funds0.49%5,584,707ADDED (+2.3%) Q3 filed Nov 13
Deerfield Management——EXITED
Perceptive Advisors——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -1.1% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

185.5083.622024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding771 of 8,857 filers
Long-only filers among them770
Change vs 2026 Q1+91 net · 719 entered · 628 exited
Shares reported, all filers100,560,352
Reported value, all filers$16.5B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryBiological Products, (No Diagnostic Substances) (SIC 2836)
Revenue · FY2025$2.9B
Net income · FY2025$478.6M
Total assets · FY2025$4.6B
Shares outstanding101,649,181
Market cap (at latest close)$16.6B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 22, 2026.

Short interest

Shares short · Oct 15, 20266,447,491
Share of shares outstanding6.34%
Days to cover4.54

Shares short at recent settlements — Jul 31, 2026: 4.4M · Aug 14, 2026: 4.6M · Aug 31, 2026: 5.1M · Sep 15, 2026: 5.0M · Sep 30, 2026: 5.9M · Oct 15, 2026: 6.4M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 22, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 22, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 15 sales by 4 insiders ($3.2M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 3, 2026MORROW GEORGE JSell100$158.18$15.8KSEC filing
Nov 3, 2026MORROW GEORGE JSell100$162.05$16.2KSEC filing
Nov 3, 2026MORROW GEORGE JSell600$163.71$98.2KSEC filing
Nov 3, 2026MORROW GEORGE JSell1,226$164.74$202.0KSEC filing
Nov 3, 2026MORROW GEORGE JSell908$165.71$150.5KSEC filing
Nov 3, 2026MORROW GEORGE JSell1,466$166.77$244.5KSEC filing
Nov 3, 2026MORROW GEORGE JSell1,500$167.72$251.6KSEC filing
Nov 3, 2026MORROW GEORGE JSell1,300$168.53$219.1KSEC filing
Nov 2, 2026MORROW GEORGE JSell1,900$144.98$275.5KSEC filing
Nov 2, 2026MORROW GEORGE JSell4,300$145.86$627.2KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Sep 14, 2026MATTHEW C ABERNETHYOfficer2,311$361.0KSep 14, 2026SEC filing
Sep 14, 2026DAVID WARREN BOYEROfficer4,714$736.4KSep 14, 2026SEC filing
Sep 9, 2026ERIC BENEVICHOfficer2,154$334.2KSep 9, 2026SEC filing
Jul 10, 2026INGRID DELAETOfficer4,367$788.5KJul 10, 2026SEC filing
Jul 9, 2026DARIN LIPPOLDTOfficer10,000$1.8MJul 9, 2026SEC filing
Jul 7, 2026INGRID DELAETOfficer14,571$2.5MJul 7, 2026SEC filing
Jun 29, 2026DARIN LIPPOLDTOfficer9,800$1.7MJun 29, 2026SEC filing
Jun 26, 2026DARIN LIPPOLDTOfficer200$32.8KJun 26, 2026SEC filing
Jun 5, 2026STEPHEN SHERWINDirector25,000$4.2MJun 5, 2026SEC filing
Jun 2, 2026JULIE COOKEOfficer36,937$5.9MJun 2, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Jul 27, 2026JPMORGAN CHASE & CO.SC 13G/A6,338,2406.3%Jun 30, 2026SEC filing
Apr 30, 2026Vanguard Capital ManagementSC 13G5,257,9415.2%Mar 31, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Jan 21, 2026JPMORGAN CHASE & CO.SC 13G5,198,0845.2%Dec 31, 2025SEC filing
May 14, 2025Dodge & CoxSC 13G5,534,6245.6%Mar 31, 2025SEC filing
Apr 28, 2025BlackRock, Inc.SC 13G/A12,052,27112.1%Mar 31, 2025SEC filing
Mar 6, 2025The Vanguard GroupSC 13G/A10,129,68710.2%Feb 28, 2025SEC filing
Feb 5, 2025STATE STREET CORPORATIONSC 13G4,891,1374.8%Dec 31, 2024SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 141 Lobbying Disclosure Act filings named this company as client, 2017–2026; most common issues: Health Issues (92), Medicare/Medicaid (86), Pharmacy (63).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Growth — Revenue up every year for 5 straight years

· Graham — Sound finances and a long run of profits

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

Key figures

· Growth — Latest revenue: $2.9B · 5-yr revenue CAGR: 22.3% · Straight growth years: 9

· Graham — Current ratio: 3.39 · Straight profitable years: 8 · Debt ratio: 0.42 · Latest net income: $478.6M

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.65 · Operating cash flow: $782.7M · Net income: $478.6M

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Share count tripled (3x)1100.0%+5.9%+5.6%+0.3%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold NBIX — ranked by lift, the co-holding pattern described in Methodology: AMGEN INC (AMGN) · GILEAD SCIENCES, INC. (GILD) · Taysha Gene Therapies, Inc. (TSHA) · BIOGEN INC. (BIIB) · Immunovant, Inc. (IMVT) · REPLIGEN CORP (RGEN) · BIO-TECHNE Corp (TECH) · Vaxcyte, Inc. (PCVX).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 2, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Sep 28, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain OfficersSEC filing
Jul 31, 2026 · 8-K/A9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

AMGEN INC (AMGN) · Track Record: how the signals scored · Practice timing on NBIX

One email a week: the week’s new filings and research. Subscribe free

← NBIS  ·  NBR →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.